Headache News and Research

Latest Headache News and Research

Health costs, disability issues cause concern among people nearing retirement

USA Today reports on new poll findings that indicate health care costs are a prominent fear among older workers. Also, Reuters reports on what might be behind the recent rise in disability claims among people in that same age group.

7 May 2012

Positive results from Dainippon Sumitomo Pharma's LATUDA trials for bipolar I depression

Dainippon Sumitomo Pharma Co., Ltd. announced today results from two Phase 3 clinical trials designed to evaluate the efficacy and safety of LATUDA as adjunctive therapy and monotherapy, respectively, in patients with bipolar I depression (PREVAIL 1 and PREVAIL 2; PRogram to EValuate the Antidepressant Impact of Lurasidone).

7 May 2012

Teva announces new data from women's health franchise

Teva Women's Health today announced new data from the Company's expanding women's health franchise will be featured at the 60th Annual Clinical Meeting of the American Congress of Obstetricians and Gynecologists (ACOG) in San Diego, California, May 5-9, 2012.

5 May 2012

SC formulation of Genentech’s ACTEMRA shows promise against RA

Genentech, a member of the Roche Group, today announced that the SUMMACTA study met its primary endpoint, showing comparable efficacy (non-inferiority) of the subcutaneous (SC) formulation of ACTEMRA (tocilizumab) 162mg weekly compared to 8 mg/kg ACTEMRA intravenous (IV) formulation every four weeks.

3 May 2012

FDA approves Protalix, Pfizer’s ELELYSO for treatment of type 1 Gaucher disease

Pfizer Inc. and Protalix BioTherapeutics, Inc. announced today that the United States (U.S.) Food and Drug Administration (FDA) approved ELELYSO (taliglucerase alfa) for injection, an enzyme replacement therapy (ERT) for the long-term treatment of adults with a confirmed diagnosis of type 1 Gaucher disease.

2 May 2012

Electrical brain stimulation technology may prevent migraine attacks

Migraine pain sits at the upper end of the typical pain scale - an angry-red section often labeled "severe." At this intensity, pain is debilitating. Yet many sufferers do not get relief from - or cannot tolerate - over-the-counter and commonly prescribed pain medications.

2 May 2012

Pfizer receives FDA approval for Elelyso to treat Type 1 Gaucher disease

The U.S. Food and Drug Administration today approved Elelyso (taliglucerase alfa) for long-term enzyme replacement therapy to treat a form of Gaucher disease, a rare genetic disorder.

2 May 2012

Antibiotic effective for plague gets FDA nod

Federal regulators – The Food and Drugs Administration (FDA), have approved use of an antibiotic to treat plague, an extremely rare, sometimes-fatal bacterial infection.

30 Apr 2012

FDA approves Levaquin for plague

The U.S. Food and Drug Administration today approved Levaquin (levofloxacin) to treat patients with plague, a rare and potentially deadly bacterial infection. The agency also approved the drug to reduce the risk of getting plague after exposure to Yersinia pestis, the bacterium that causes the disease.

30 Apr 2012

BTG launches Voraxaze for treatment of toxic plasma methotrexate

BTG International Inc., the specialist healthcare company today announces the launch of Voraxaze (glucarpidase) in the US. Voraxaze is indicated for the treatment of toxic plasma methotrexate concentrations (>1 micromole per liter) in patients with delayed methotrexate clearance due to impaired renal function.

30 Apr 2012

Ramson leaves can be confused with poisonous plants

The National Food Institute, Technical University of Denmark has assessed the possible toxic effects of eating ramson, which in recent years has become a popular plant to gather and eat in Denmark. As such, ramson does not contain any substances that are toxic for humans, but they can be confused with poisonous plants. In particular, before flowering, ramson leaves can be confused with autumn crocus and lily of the valley. Several cases of poisoning have been reported in other European countries with fatal consequences as a result of this confusion.

30 Apr 2012

VIVUS receives FDA approval for Stendra to treat erectile dysfunction

The U.S. Food and Drug Administration today approved Stendra (avanafil), a new drug to treat erectile dysfunction.

30 Apr 2012

FDA approves VIVUS’ STENDRA for treatment of erectile dysfunction

VIVUS, Inc. today announced that the U.S. Food and Drug Administration (FDA) has approved STENDRA (avanafil) tablets for the treatment of erectile dysfunction (ED), marking the first new prescription agent approved in nearly a decade for the condition that afflicts as many as 30 million men in the U.S.

30 Apr 2012

FDA approves Novartis’ Afinitor for treatment of renal angiomyolipomas and TSC

Novartis Pharmaceuticals Corporation announced today that the US Food and Drug Administration (FDA) approved Afinitor (everolimus) tablets for the treatment of adult patients with kidney tumors known as renal angiomyolipomas and tuberous sclerosis complex (TSC), who do not require immediate surgery.

27 Apr 2012

GSK receives FDA approval for Votrient to treat advanced soft tissue sarcoma

The U.S. Food and Drug Administration today approved Votrient (pazopanib) to treat patients with advanced soft tissue sarcoma who have previously received chemotherapy. Soft tissue sarcoma is a cancer that begins in the muscle, fat, fibrous tissue, and other tissues.

27 Apr 2012

Positive top-line results from Shire’s Vyvanse Phase 2 study on binge eating disorder

Shire plc, the global specialty biopharmaceutical company, today announced positive top-line results from a Phase 2 study to evaluate the safety and efficacy of Vyvanse (lisdexamfetamine dimesylate) Capsules, (CII) in adults with binge eating disorder.

27 Apr 2012

Novartis receives FDA approval for Afinitor to treat renal angiomyolipomas caused by TSC

The U.S. Food and Drug Administration approved Afinitor (everolimus), the first drug approved specifically to treat non-cancerous kidney tumors (renal angiomyolipomas) not requiring immediate surgery in patients with tuberous sclerosis complex.

27 Apr 2012

Latest AAN/AHS guidelines can help prevent migraine attacks

The latest American Academy of Neurology/American Headache Society Guidelines released this week outline evidence-based and effective treatments that can prevent migraine attacks and lessen their severity.

26 Apr 2012

FDA issues complete response letter to Takeda’s NDAs for type 2 diabetes investigational therapies

Takeda Pharmaceutical Company Limited and its wholly-owned subsidiary, Takeda Global Research & Development Center, Inc. today announced that the company received a complete response letter from the United States (U.S.) Food and Drug Administration (FDA) regarding New Drug Applications (NDAs) for alogliptin and fixed-dose combination (FDC) alogliptin and pioglitazone.

26 Apr 2012

World Malaria Day observed

The 25th of April was observed as World Malaria Day. According to Ray Chambers, the U.N. secretary-general's special envoy for malaria, there has been a marked progress in reducing malaria deaths using bed nets, insecticide spray and drugs. He cited a World Health Organization report in December which used figures from 2010, saying malaria deaths had decreased by over one-third. Since then, he said at a news conference Monday, the world has delivered 160 million additional bed nets “so we expect the number of deaths to be much less now.”

25 Apr 2012